Endpoint
Diastolic blood pressure (office/clinic)
CAT:outcome/office-diastolic-blood-pressurereported in mmHg2 findings from 2 compounds
What moved it
How to read these marks2 findings · 2 compounds · 1 null · by evidence strength
| Compound | Direction | Findings | Strongest evidence |
|---|---|---|---|
| nitrate | down | 1 | Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. |
| resveratrol | no effect | 1 | Evidence strength: limited. Human evidence with several recorded weaknesses, or a design that tops out at limited. |
Reported to move it
1 finding
nitrate — decreases
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“The reduction in systolic blood pressure after dosing between treatment conditions was not significantly different, however, the reduction in diastolic blood pressure was greater in the nitrate supplemented group (7±8 nitrate vs. 1±8mmHg placebo; p = 0.008).”
Quoted verbatim from Acute Dietary Nitrate Supplementation and Exercise Performance in COPD: A Double-Blind, Placebo-Controlled, Randomised Controlled Pilot Study.. - Study
- crossover
- Dose
- 140 mL beetroot juice containing 12.9 mmol nitrate, single dose
- Population
- 21 adults with COPD (GOLD II-IV); change in resting seated diastolic pressure from baseline to 3 h after a single dose, nitrate-rich versus nitrate-depleted beetroot juice
Acute Dietary Nitrate Supplementation and Exercise Performance in COPD: A Double-Blind, Placebo-Controlled, Randomised Controlled Pilot Study.2015PMID:26698120An author is affiliated with a producerPermalink
Measured, no effect detected
1 finding
resveratrol — no detected effect on
LimitedEvidence strength: limited. Human evidence with several recorded weaknesses, or a design that tops out at limited.FindingNull result“Data analyzed using the multivariate ANOVA model revealed that resveratrol’s effects on systolic and diastolic blood pressure were not statistically significant compared with placebo (Table 3).”
Quoted verbatim from Preliminary, randomized, double-blinded, placebo-controlled cross-over study with resveratrol in hypertensive patients.. - Study
- crossover
- Participants
- 16
- Duration
- 4 weeks
- Dose
- 500 mg twice daily, oral
- Population
- pre-hypertensive and stage-1 hypertensive adults aged 20-60 years, Iran; primary outcome; 2 x 2 crossover, 16 completers analysed
Preliminary, randomized, double-blinded, placebo-controlled cross-over study with resveratrol in hypertensive patients.2025PMID:40854984Permalink
How it is measured
Diastolic blood pressure taken at a clinic visit with the participant seated after a stated rest period, by auscultatory or validated automated cuff sphygmomanometer, averaged across the readings of that visit.
Sources cited
2 papers
- Subject
- diastolic blood pressure (office/clinic)
- Findings
- 2
- Papers
- 2
Preliminary, randomized, double-blinded, placebo-controlled cross-over study with resveratrol in hypertensive patients.record2025PMID:408549841 finding
Acute Dietary Nitrate Supplementation and Exercise Performance in COPD: A Double-Blind, Placebo-Controlled, Randomised Controlled Pilot Study.record2015PMID:266981201 finding